UPDATES ON MANAGEMENT OF GASTRIC CANCER IN KOSOVO
Session
Pharmaceutical and Natural Sciences
Description
One of the leading causes of cancer-related deaths worldwide is gastric cancer. In order to choose the best course of treatment for gastric adenocarcinoma, a multidisciplinary approach is essential. Systemic chemotherapy, radiation, surgery, immunotherapy, and targeted therapy have all demonstrated efficacy in this disease. The usual cytotoxic chemotherapy for localized disease may have reached a plateau with the acceptance of triplet chemotherapy for resectable gastric cancer. Molecular subtype classification of gastric cancer is opening the door to individualized treatment. Systemic therapy approaches are becoming more and more driven by biomarkers, particularly microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein-Barr virus. These biomarkers enable the identification of populations most likely to benefit from immunotherapy and targeted therapy. The less differentiated histologic subtypes of gastric cancer and those without indicators of immunotherapy activity nonetheless present significant research prospects.
Keywords:
Gastric cancer, chemotherapy, biomarkers, management
Proceedings Editor
Edmond Hajrizi
ISBN
978-9951-550-95-6
Location
UBT Lipjan, Kosovo
Start Date
28-10-2023 8:00 AM
End Date
29-10-2023 6:00 PM
DOI
10.33107/ubt-ic.2023.121
Recommended Citation
Ejupi, Valon; Dragusha, Shpend; Qazimi, Bujar; and Jakupi, Arianit, "UPDATES ON MANAGEMENT OF GASTRIC CANCER IN KOSOVO" (2023). UBT International Conference. 16.
https://knowledgecenter.ubt-uni.net/conference/IC/PNS/16
UPDATES ON MANAGEMENT OF GASTRIC CANCER IN KOSOVO
UBT Lipjan, Kosovo
One of the leading causes of cancer-related deaths worldwide is gastric cancer. In order to choose the best course of treatment for gastric adenocarcinoma, a multidisciplinary approach is essential. Systemic chemotherapy, radiation, surgery, immunotherapy, and targeted therapy have all demonstrated efficacy in this disease. The usual cytotoxic chemotherapy for localized disease may have reached a plateau with the acceptance of triplet chemotherapy for resectable gastric cancer. Molecular subtype classification of gastric cancer is opening the door to individualized treatment. Systemic therapy approaches are becoming more and more driven by biomarkers, particularly microsatellite instability (MSI), programmed cell death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein-Barr virus. These biomarkers enable the identification of populations most likely to benefit from immunotherapy and targeted therapy. The less differentiated histologic subtypes of gastric cancer and those without indicators of immunotherapy activity nonetheless present significant research prospects.